Avenue Therapeutics, Inc (ATXI)

Etorro trading 970x250
Avenue Therapeutics, Inc (ATXI) Logo

About Avenue Therapeutics, Inc

Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was founded in 2015 and is based in New York, New York. Effective as of December 31, 2019, Avenue Therapeutics, Inc. operates as a subsidiary of InvaGen Pharmaceuticals, Inc. Address: 2 Gansevoort Street, New York, NY, United States, 10014

Avenue Therapeutics, Inc News and around…

Latest news about Avenue Therapeutics, Inc (ATXI) common stock and company :

12 Health Care Stocks Moving In Monday's Intraday Session
25 Oct, 2021 FinancialContent

Gainers Jaguar Health (NASDAQ:JAGX) shares increased by 14.64% to $2.08 during Monday's regular session. The current ...

12 Health Care Stocks Moving In Monday's Pre-Market Session
25 Oct, 2021 FinancialContent

Gainers Kiromic BioPharma (NASDAQ:KRBP) stock increased by 28.64% to $2.47 during Monday's pre-market session. The ...

Avenue Therapeutics Receives Interim Response to its Formal Dispute Resolution Request from U.S. Food and Drug Administration Office of New Drugs
25 Oct, 2021 Yahoo! Finance

Office of New Drugs concludes that additional input is needed, and U.S. Food and Drug Administration will convene an Advisory Committee meetingNEW YORK, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced that it has received a written interim response from the Office of New Drugs (“OND”) of the U.S. Food and Drug Administration (“FDA”). The letter indicated

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
08 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
07 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
06 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
05 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
30 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
21 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Friday
27 Aug, 2021 FinancialContent

Before 10 a.m. ET on Friday, 29 stocks hit new 52-week lows. Significant Points: Campbell Soup (NYSE:CPB) was the ...

Amneal (AMRX) Parkinson's Candidate Successful in Pivotal Study
26 Aug, 2021 Yahoo! Finance

Amneal's (AMRX) IPX-203 increases "Good On" time by 1.55 hours per dose versus immediate-release CD/LD in patients with Parkinson's disease.

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
18 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
17 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
06 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
28 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
27 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Sum Up The Pieces: VTI Could Be Worth $248
22 Jul, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Total Stock Market ETF (VTI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $247.86 per unit.

The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
20 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study
16 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
15 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues
14 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Tuesday
13 Jul, 2021 FinancialContent

Before 10 a.m. ET on Tuesday, 48 companies set new 52-week lows. Interesting Highlights: Marqeta ...

12 Health Care Stocks Moving In Tuesday's After-Market Session
06 Jul, 2021 FinancialContent

Gainers Opiant Pharmaceuticals (NASDAQ:OPNT) stock increased by 35.04% to $17.9 during Tuesday's after-market session. Opiant ...

Monday’s Pre-Market: Here’s What You Need to Know Before the Market Opens
21 Jun, 2021 Yahoo! Finance

U.S. stock futures jumped on Monday as investors await comments from the Fed members at an Official Monetary and Financial Institutions Forum panel, to be held virtually. Additionally, the monthly Chicago Fed National Activity Index for May will be released today. S&P, Dow, and Nasdaq futures were in the green at the time of writing, with 0.5%, 0.3%, and 0.3% higher trading, respectively. NextDecade Corporation (NEXT), Pluristem Therapeutics (PSTI), Avenue Therapeutics Inc. (ATXI), and Hancock J

Look Under The Hood: IWO Has 22% Upside
18 Jun, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Russell 2000 Growth ETF (IWO), we found that the implied analyst target price for the ETF based upon its underlying holdings is $371.66 per unit.

44 Biggest Movers From Yesterday
16 Jun, 2021 FinancialContent

Gainers Alzamend Neuro, Inc. (NASDAQ: ALZN) shares jumped 170% to close at $13.50 on Tuesday after the company priced its IPO at ...

34 Stocks Moving In Tuesday's Mid-Day Session
15 Jun, 2021 FinancialContent

Gainers HMG/Courtland Properties, Inc. (NYSE: HMG) shares surged 133% to $27.80. Alfi, Inc. (NASDAQ: ALF) shares jumped 82.1% to ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
15 Jun, 2021 FinancialContent

Gainers Clearside Biomedical (NASDAQ:CLSD) stock increased by 50.99% to $4.56 during Tuesday's pre-market session. ...

The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda
15 Jun, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
15 Jun, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back, traders, and good morning! We're starting off the day with a look at the biggest pre-market stock movers for Tuesday. The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now It doesn’t matter if you have $500 in savings or $5 million. Do this now. Top Stock Picker Reveals His Next Potential 500% Winner

Avenue Therapeutics, Inc (ATXI) is a NASDAQ Common Stock listed in , ,

970x250